Traws Pharma (TRAW)

Phase 1 Ratutrelvir Results Announced With Plans To Move To Phase 2a


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
October 1, 2024
Report ID: 27006
Already Registered?
Click the Get Report button to login and view the full report, with price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Register Now to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Traws Pharma, Inc.
Traws Pharma, Inc.
Healthcare
Biotechnology
Ticker
TRAW
Current Price
$5.0713 7.95%
Market Cap
$15.3M
Price Target
Refer to Report
Volume
10.1K
52wk Range
$4.06 - $27.5
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.